Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 14847 total
FirstCash Holdings heads into its October 22 earnings date with short sellers adding exposure at a steady clip while options traders make the starkest bullish bet in months. The options market is telling the clearest…
Kodiak Sciences enters the final stretch of September with a notable divergence: most of its institutional holders remain constructive, Goldman Sachs just re-entered coverage with a cautious stance, and short sellers…
Eton Pharmaceuticals enters the final stretch before its November 12 earnings date with an interesting split: short sellers quietly rebuilding positions against a backdrop of overwhelmingly bullish Street sentiment and…
Krystal Biotech heads into the final week of September with two sharply contrasting signals: Goldman Sachs just returned to the stock with a bullish stamp, while options traders have swung to their most defensive…
Baker Hughes enters the final week of September having quietly done what few oilfield services names managed this month: hold its ground. The stock closed Friday at $57.83, up 1% on the week, even as the broader sector…
Everpure delivered one of the technology hardware sector's standout weeks, gaining 21% to close at $126 — and the most compelling story isn't where shorts are positioned, but how emphatically the analyst community has…
Element Solutions Inc heads into its October 27 earnings date with a sharp 9% weekly rally behind it, a clean short book, and a Street that remains broadly bullish but has quietly pulled price targets lower — creating…
TG Therapeutics enters the final stretch of Q3 with an unusual split: the stock is holding near multi-year highs while short sellers are quietly rebuilding positions at a pace that puts short interest among the…
MARA Holdings enters the final week of September with an unusual configuration: short sellers are pulling back even as the stock slides, and the borrow market is quietly tightening — a tension that makes the current…
Harrow, Inc. heads into the final week of September with a peculiar split: options traders are the most bullish they've been all year, while short sellers are quietly adding to an already-heavy position — and borrow…
XBI, the SPDR S&P Biotech ETF, enters the final days of September with a striking disconnect: options traders are at their most bearish in twelve months, yet the lending market has quietly loosened over the past…
DAL heads into its October 9 earnings report with short sellers cutting positions sharply, options traders turning distinctly bullish, and Warren Buffett quietly building a larger stake — a rare alignment of signals…
EnerSys enters the final week of September with a sharp contradiction at its core — short interest has jumped to its highest level in months while options traders have turned strikingly bullish. Short sellers have been…
Cytokinetics enters the final week of September in a difficult position. The stock has shed 6% over the past week and 16.5% over the past month, closing at $64.66 — well below the levels where the Street sees fair…
SBA Communications heads into the final week of September with a sharp selloff, rising short interest, and options traders at their most defensive posture in a year. The price action tells the dominant story. SBAC…
MRK enters the final week of September with a notable disconnect: the Street has spent the past month racing targets higher, yet the stock has slipped 5% over that same period — leaving a widening gap between analyst…
Extreme Networks heads into its October 28 earnings date with short sellers backing away — even as the stock drifts lower and options traders edge more cautious. The headline short-interest move is the sharpest in…
DXP Enterprises heads into the final week of September with a stock up nearly 4% on the week and shorts steadily unwinding — a quiet but consistent message from the data. The short side has been retreating for weeks.…
BSX heads into its October 21 earnings call with a striking divergence: the CEO spent $9 million buying stock in early August, yet the analyst community has spent September methodically trimming targets. The insider…
Allstate enters the final week of September in an awkward position: the stock has shed nearly 9% over seven sessions to $227.60, yet the options market is flashing one of its most bullish signals of the past year. The…
